Top News

Novocure, Zai shares rally after lung-cancer treatment meets primary endpoint in study


Shares of Novocure Ltd.

soared 71.5% in premarket trading on Thursday after the company said the experimental non-small cell lung cancer treatment it’s developing with Zai Lab Ltd.

met the primary endpoint in an open-label clinical trial, which assesses tumor treating fields in combination with other cancer therapies. U.S.-listed shares of Zai gained 31.4%. The companies said they plan to seek premarket approval in the U.S. in the second half of the year. Novocure’s stock is down 2.4% over the past year, while Zai’s shares have declined 37.3%. The S&P 500

is down 19.6%.

Stock Futures Drop With Bonds on Strong Labor Data: Markets Wrap

Previous article

Bed Bath & Beyond warns it may go out of business, stock tanks to lowest levels in 30 years

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Top News